Time to go All-In on Celsion?
Celsion (CLSN) is a great story stock. It recently announced their Phase III trial results for liver cancer will be released by the end of January 2013. This will be a top-line release of a multinational, double-blind, placebo-controlled study of primary liver cancer. The results could make or break the company as its future pipeline is dependent on ThermoDox succeeding.
This upcoming catalyst is likely to have a huge impact on the company's valuation. The company has a current market cap of $287 million, but this will likely be drastically different by the end of the month. The CEO of Celsion has stated that this liver cancer treatment will have the potential to generate yearly revenues of $1 billion.
Mastery Bottom Line
Look for a good entry point before betting the farm on CLSN. Shares could dip down to touch the 50 day MA due to some investors not wanting to risk holding through the FDA results. A $7 - $7.50 share price would provide a great buying opportunity.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Trade Like A Market Wizard - An Interview With Mark Andrew Ritchie | ZeroHedge
- Threat Of Cyber War – “Other Reason To Own Physical Gold” – Rickards | ZeroHedge
- Quantum Geopolitics | Financial Sense
- Is the U.S. Really the World’s Top Oil Producer? | Financial Sense
- Third Bailout Generates New Political Division in Greece | Financial Sense
- Congress Proposes Fraudulent New Law To "Fix" Social Security | ZeroHedge
- The Disgusting #hashtag | iBankCoin.com
The most relevant financial news and articles from the Internets
- Air strikes and clashes shatter Yemen truce | Business Insider
- A new Apple TV is coming in September | Business Insider
- A Cincinatti prosecutor has released... | Business Insider
- A JCPenney employee says she was sent home for... | Business Insider
- Brazil raises a key interest rate as it teeters on the... | Business Insider
- Climate change might make your favorite wine disappear | Business Insider
- BRADY FIRES BACK: There is no 'smoking gun' and this controversy is... | Business Insider